reason report
bottom line spoke op manag discuss
recent disclos tipifarnib regulatori updat overal continu
impress manag abil execut tipifarnib
develop strategi view recent disclos feedback
end phase ii fda meet detail plan registration-
direct trial tipifarnib hra mutant hrasm squamou cell
carcinoma head neck scchn encourag view
conserv assumpt incorpor plan registration-
direct studi provid underappreci sourc upsid
ensur reason enrol timelin view well
posit continu view tipifarnib activ drug
manag safeti profil recal licens world-wide right
tipifarnib indic virolog janssen op
previous evalu tipifarnib broadli across variou hematolog
solid tumor limit success believ precis
medicin approach develop tipifarnib biomarker-defin patient
offer opportun improv past effort also updat
model reflect recent disclos financi result
increas pt previous reiter op
encourag regulatori updat detail plan registration-
execut manag recent disclos feedback end
phase ii meet fda plan initi single-arm
registration-direct studi tipifarnib least recurr
metastat patient hrasm scchn object respons rate
orr primari endpoint studi aim-hn expect
initi recal manag previous set expect
reasonably-s pivot studi patient upper
end link studi enrol patient broadli group
categori post-platinum potenti non-
platinum would relev asia manag indic
expect enrol coupl patient group line
post-adjuv post-primari refractori platinum
also plan initi hra screen outcom studi seq-
hn evalu scchn patient hrasm importantli
seq-hn studi facilit identif patient potenti
enrol aim-hn studi on-going phase ii studi run-
hn elig aim-hn
multipl dr tgr
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
underappreci aspect studi design spoke
manag highlight key point aim-hn studi
small single-ag single-arm studi support acceler
approv consist expect set manag
view reflect continu strong manag execut
studi could line trial requir patient
receiv prior immun therapi safeti data base
adequ support submiss extens data gener
past studi agenc consid total
data includ result seq-hn studi respect type
approv post-approv commit believ import
seq-hn studi underappreci studi facilit
identif patient aim-hn studi well establish
true orr hrasm popul current poorli understood
aim-hn studi power detect differ
null hypothesi orr estim orr line therapi
recurrent/metastat diseas orr tipifarnib notabl
orr hrasm scchn patient could much lower
manag highlight seen respons
agent hrasm subset littl data avail
hrasm subset tipifarnib orr significantli dwarf true orr
hrasm patient could ultim repres upsid post-approv
expect reason enrol timelin manag
yet provid specif guidanc expect enrol
timelin believ studi could take year enrol
view posit given past enrol issu previous disclos
manag disclos aim-hn studi requir
clinic site world-wide note on-going phase ii studi
run-hn site manag note enrol
patient per month order complet enrol studi
year enrol would need improv patient per month
could accomplish site current rate
view plan site aim-hn studi conserv
approach manag ensur reason enrol timelin
catalyst timelin includ preclin data upcom
american associ cancer research annual meet
includ preclin tipifarnib data hrasm squamou non-
small cell lung cancer nsclc model preclin biomark
erk inhibitor data squamou cell carcinoma initi seq-hn
aim-hn respect addit updat
on-going phase ii tipifarnib studi hrasm scchn run-hn
phase dose-escal data initi proof-
of-concept studi tipifarnib hrasm nsclc spanish
lung cancer group addit tipifarnib data hematolog
malign like submiss ind
applic menin-ml inhibitor
rate share outperform view lead pipelin program
tipifarnib farnesyltransferas inhibitor activ drug manag safeti profil
licens world-wide right tipifarnib indic virolog janssen
previous evalu tipifarnib broadli across variou hematolog solid tumor
limit success believ precis medicin approach develop tipifarnib
biomarker-defin patient offer opportun improv past effort base review
literatur medacorp kol check believ investor focu continu
lead clinic asset tipifarnib inhibitor menin-ml mix lineag
price target base blend dcf analysi revenu
multipl analysi assign valu probability-weight us sale tipifarnib hra mutant
squamou cell carcinoma head neck scchn probabl success hra
mutant squamou non-smal cell lung cancer nsclc probabl success hra
mutant solid tumor probabl success peripher cell lymphoma
probabl success myelodysplast syndrom md probabl success
cmml probabl success assum royalti ex-u tipifarnib sale
futur partnership earlier stage program menin-ml inhibitor repres
upsid valuat use discount rate termin growth rate
pipelin program face clinic regulatori develop risk well commerci
intellectu properti risk also face execut risk financi risk may
addit financ need turn cash flow posit
leerink partner estim compani file
chang
oper
invest
financ
leerink partner estim compani file
pipelin upcom event
janssen
potenti acut
hrasm solid tumor
